ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.
RxSight’s management is scheduled to participate in a fireside chat on Wednesday, September 6, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/news-events/investor-calendar.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley Thunen
RxSight, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.71 |
Daily Change: | -0.57 -6.14 |
Daily Volume: | 598,634 |
Market Cap: | US$356.410M |
August 14, 2025 August 07, 2025 August 04, 2025 May 07, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load